The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients

被引：0
|
作者：
Elisabetta Munzone
Alessandra Fabi
Giuseppe Buono
Roberta Caputo
Emilia Montagna
Mara Negri
Francesco Nuzzo
Antonella Palazzo
Ida Paris
Luca Conti
Anna Baggi
Jean Marie Franzini
Michelino De Laurentiis
机构：
[1] Istituto Europeo di Oncologia,Precision Medicine Unit in Senology
[2] IRCCS,Medical Oncology Unit Fondazione
[3] Fondazione Policlinico Universitario Agostino Gemelli,Ginaecological Oncology Unit Fondazione
[4] National Cancer Institute “Fondazione Pascale”,Life Sciences Division
[5] Policlinico Universitario Agostino Gemelli,undefined
[6] Policlinico Universitario Agostino Gemelli,undefined
[7] Business Integration Partners,undefined
来源：
Drugs & Therapy Perspectives | 2023年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：432 / 446
页数：14
相关论文
共 50 条
  • [21] Impact of subcutaneous versus intravenous administration of pertuzumab and trastuzumab (PH) for the treatment of HER2-positive breast cancer in Montenegro
    Saric, N. Cicmil
    Lekic, S.
    Lakicevic, J.
    Todorovic, V.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S72 - S72
  • [22] Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
    O'Shaughnessy, Joyce
    Sousa, Susana
    Cruz, Josefina
    Fallowfield, Lesley
    Auvinen, Paivi
    Pulido, Catarina
    Cvetanovic, Ana
    Wilks, Sharon
    Ribeiro, Leonor
    Burotto, Mauricio
    Klingbiel, Dirk
    Messeri, Dimitri
    Alexandrou, Ari
    Trask, Peter
    Fredriksson, Judy
    Machackova, Zuzana
    Stamatovic, Ljiljana
    EUROPEAN JOURNAL OF CANCER, 2021, 152 : 223 - 232
  • [23] White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example
    Christian Jackisch
    Federico Manevy
    Suzanne Frank
    Nicki Roberts
    Jason Shafrin
    Advances in Therapy, 2022, 39 : 833 - 844
  • [24] White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example COMMENT
    Jackisch, Christian
    Manevy, Federico
    Frank, Suzanne
    Roberts, Nicki
    Shafrin, Jason
    ADVANCES IN THERAPY, 2022, 39 (02) : 833 - 844
  • [25] Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
    Angelica L. Quartino
    Hanbin Li
    Jin Y. Jin
    D. Russell Wada
    Mark C. Benyunes
    Virginia McNally
    Lucia Viganò
    Ihsan Nijem
    Bert L. Lum
    Amit Garg
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 353 - 361
  • [26] Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study (vol 88, 499, 2021)
    Wang, Bei
    Deng, Rong
    Hennig, Stefanie
    Badovinac Crnjevic, Tanja
    Kaewphluk, Monika
    Kagedal, Matts
    Quartino, Angelica L.
    Girish, Sandhya
    Li, Chunze
    Kirschbrown, Whitney P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 571 - 572
  • [27] heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+, HER2+advanced breast cancer
    Kuemmel, Sherko
    Harper-Wynne, Catherine
    Park, Yeon H.
    Franke, Fabio
    De laurentiis, Michelino
    Schumacher-Wulf, Eva
    Eiger, Daniel
    Heeson, Sarah
    Shivhare, Mahesh
    Restuccia, Eleonora
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2023, 83 (05)
  • [28] IMPACT ASSOCIATED WITH PERTUZUMAB AND TRASTUZUMAB SC AND IV FORMULATIONS UTILIZATION IN METASTATIC HER2-POSITIVE BREAST CANCER PATIENTS TREATED IN BRAZILIAN SUS
    Monteiro, I
    Cordeiro, F.
    Martins, T.
    Medeiros, C.
    VALUE IN HEALTH, 2024, 27 (12) : S68 - S68
  • [29] Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
    Liu, Yan-cui
    Ma, Ying
    An, Ning
    Sun, Ping
    Wang, Ying
    Sun, Cheng
    MEDICINE, 2019, 98 (38)
  • [30] ADDING PERTUZUMAB IN NEOADJUVANT TREATMENT OF PATIENTS WITH HER2+ BREAST CANCER IN SPAIN: A COST OFFSETS STUDY
    Albanell, J.
    Ciruelos, E.
    Colomer, R.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Tournier, C.
    Thuresson, P.
    Schleich, W.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 117 : 42 - 42
12345